Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Galectin Therapeutics Inc.NASDAQ: GALT
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $4.08M fell 48.4% year over year, ahead of the -60.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 21.2% from the prior quarter. Over 3 fiscal years it compounded at -19.4% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -48.4% holds above the trailing-twelve-month pace of -60.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 20.09M USD
- Year-over-year change
- -52.7%
- 4-year CAGR
- -9.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.09M | -52.7% |
| FY2024 | 2024-12-31 | 42.43M | +11.5% |
| FY2023 | 2023-12-31 | 38.07M | -0.7% |
| FY2022 | 2022-12-31 | 38.35M | +27.1% |
| FY2021 | 2021-12-31 | 30.18M | — |
Operating Expenses vs competitors
How GALT compares with its peers on the latest reported figures
- GALT's LTM Mar 2026 operating expenses of $16.27M is the lowest of the 10 companies compared; the peer median is $81.97M.
- Its year-over-year change of -60.0% is the lowest of 9, against a peer median of +15.3%.
- Over three fiscal years its annual growth of -19.4% compares with a peer median of +8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $213.72M | -20.2% | -1.0% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $132.21M | +50.3% | +85.1% | — |
| LTM Mar 2026 | $118.05M | +15.1% | +23.2% | — | |
| LTM Mar 2026 | $97.04M | -13.5% | -7.3% | 5239.8% | |
| LTM Mar 2026 | $81.97M | -16.5% | +2.5% | 227697.2% | |
| LTM Mar 2026 | $78.76M | +15.4% | +5.5% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $46.78M | — | +121.2% | — |
| LTM Mar 2026 | $46.29M | +25.4% | +8.5% | — | |
| LTM Mar 2026 | $36.74M | +26.3% | +34.9% | — | |
| LTM Mar 2026 | $16.27M | -60.0% | -19.4% | — | |
| Peer median (excluding GALT) | $81.97M | +15.3% | +8.5% | 116468.5% | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.82M | 31.74M | 32.13M | 36.57M | 14.29M |
| Selling, General & Admin | 6.36M | 6.62M | 5.94M | 5.86M | 5.8M |
| Operating Expenses | 30.18M | 38.35M | 38.07M | 42.43M | 20.09M |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| EBITDA | (30M) | (37.71M) | (38.24M) | (41.47M) | (23.45M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (30.18M) | (38.35M) | (38.07M) | (42.43M) | (20.09M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3K | 52K | 230K | 338K | 126K |
| Interest Expense | 489K | 1.03M | 2.79M | 5.54M | 7.33M |
| Other Income / Expenses | (348K) | (424K) | (2.99M) | (4.61M) | (10.75M) |
| Income Before Tax | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| EPS (Diluted) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| Weighted Avg Shares | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
| Weighted Avg Shares (Diluted) | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.